Compare Adaptive Biotechnologies Corp (ADPT) vs Iris Energy Limited (IREN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Iris Energy Limited — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while Iris Energy Limited trades at $40.84 (market cap $14.23B). The key difference: Iris Energy Limited is far larger — about 4.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | IREN | |
|---|---|---|
Market Cap | $3.33B | $14.23B |
Sector | Health | Energy |
52-Week High | $22.37 | $76.41 |
52-Week Low | $10.24 | $15.40 |
Enterprise Value | $3.19B | $15.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IREN stock trades at $43.91, up 13.11% today amid speculation about a potential $22 billion Anthropic deal. The technical picture remains bearish despite the rally, with the stock missing earnings expectations for three consecutive quarters. Revenue growth appears strong with 2026 projections showing $757 million, though profitability metrics show negative ROE and ROA. Analyst consensus remains bullish with a $79.11 price target despite recent volatility.
The investment case hinges on IREN's transition from Bitcoin mining to AI infrastructure, with significant capacity expansion funded by substantial financing activities. Key risks include execution challenges in scaling operations, competitive pressure from established cloud providers, and reliance on speculative contract wins. The current valuation at 57x P/E appears stretched given negative returns on equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
